AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $521.02 ($518.45–$526.97, $4.95M total) across 8 trades on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Aug 21, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short‑term risk assessment.

02

Market read

Insider sell of nearly $5M may influence short‑term trading but is unlikely to drive major market moves.

03

What to watch

Potential upcoming clinical data releases or financing needs not disclosed in the filing.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑20

Background

Form 4 filing reveals insider transaction for United Therapeutics (NASDAQ: UTHR).

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

CEO Martine Rothblatt sold $4.95M of UTHR shares via a 10b5‑1 plan on 2026‑08‑20.

Expected impact

Potential short‑term pressure on UTHR price; limited long‑term effect.

Evidence & confidence

Sale size is material for a mid‑cap biotech, yet 10b5‑1 plans are routine and often unrelated to fundamentals.

Market effects

Sector

May prompt scrutiny of biotech insider activity but unlikely to shift sector sentiment.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond UTHR shareholders.

Counterpoint

What could challenge this read

The sale could be purely liquidity‑driven; the stock may remain stable.

Key entities

  • Company
    United Therapeutics Corp

    Biopharma company developing therapies for pulmonary arterial hypertension.

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min